Pre-treatment serum lactate dehydrogenase as a biomarker in small cell lung cancer.

Abstract:

BACKGROUND:Small cell lung cancer is a rapidly progressive disease with high fatality. No sensitive and specific biomarker to assist in managing this disease exists currently. AIM:Role of pretreatment serum lactate dehydrogenase as a biomarker in small cell lung cancer. METHODS:A hospital-based cancer registry was used to identify eligible patients from 1999 to 2009. Demographic data, lactate dehydrogenase level and clinical outcome of patients were collected for analysis. RESULTS:One hundred and sixty-eight patients were identified: 61% (n = 103) males and 39% (n = 65) females. Majority had extensive stage (67%). High lactate dehydrogenase (≥230 U/L) was present in 60.4% (n = 75); mean reading 260 U/L (range 148-898 U/L) in limited stage and 470 U/L (range 116-5462 U/L) in extensive stage. Extensive stage patients with high lactate dehydrogenase had lower treatment response rate compared to those with normal lactate dehydrogenase (39% vs 79%, P = 0.002); no difference in treatment response was seen among patients with limited stage. High lactate dehydrogenase conferred a worse survival; mean overall survivals in limited and extensive stage were 8.0 and 5.2 months, respectively, in patients with elevated lactate dehydrogenase. Those with normal lactate dehydrogenase had an overall survival of 16.5 and 8.2 months, respectively. The association remained significant after adjustment for age, sex and treatment (HR 1.8, 95% CI 1.16-2.80, P = 0.009). CONCLUSION:High pretreatment lactate dehydrogenase is a prognostic marker of survival in both stages of small cell lung cancer. It is also a predictive marker of response to therapy in extensive stage. Larger prospective studies to validate our findings would be beneficial.

journal_name

Asia Pac J Clin Oncol

authors

Hsieh AH,Tahkar H,Koczwara B,Kichenadasse G,Beckmann K,Karapetis C,Sukumaran S

doi

10.1111/ajco.12674

subject

Has Abstract

pub_date

2018-04-01 00:00:00

pages

e64-e70

issue

2

eissn

1743-7555

issn

1743-7563

journal_volume

14

pub_type

杂志文章
  • Cut-point for Ki-67 proliferation index as a prognostic marker for glioblastoma.

    abstract:INTRODUCTION:Ki-67 proliferation index (Ki-67 index) is used to quantify cell proliferation during histopathological assessment of various tumors including glioblastoma (GB). AIM:We aimed to assess correlation between Ki-67 index and overall survival in patients with GB and determine a cut-point for Ki-67 index that p...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/ajco.12826

    authors: Wong E,Nahar N,Hau E,Varikatt W,Gebski V,Ng T,Jayamohan J,Sundaresan P

    更新日期:2019-02-01 00:00:00

  • Impact of modified FOLFOX-6 for patients with gastric cancer and a gastrointestinal obstruction.

    abstract:AIM:Gastric cancer patients are normally treated with oral fluoropyrimidine and cisplatin or oxaliplatin; however, treating patients who also have a gastrointestinal obstruction is often difficult because of their poor oral intake. Instead, a modified (m)FOLFOX-6 regimen is administered, even to patients with gastroint...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/ajco.13110

    authors: Yukami H,Terazawa T,Goto M,Aoki M,Asaishi K,Yamaguchi T,Kuwakado S,Kii T,Higuchi K

    更新日期:2019-10-01 00:00:00

  • Effectiveness of image-guided radiotherapy for rectal cancer patients treated with neoadjuvant concurrent chemoradiotherapy: A population-based propensity score-matched analysis.

    abstract:AIM:The effects of image-guided radiotherapy (IGRT, an advanced RT technology) have been debated in the literature. We compared the outcomes of locally advanced rectal cancer (LARC) patients treated with neoadjuvant concurrent chemoradiotherapy (NCCRT; with vs without IGRT) in a large population-based propensity score ...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/ajco.13196

    authors: Li CC,Liang JA,Chen WT,Chien CR

    更新日期:2019-10-01 00:00:00

  • Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: a multicenter, open-label, single-arm phase II study.

    abstract:AIMS:Currently, the only standard systemic treatment for advanced hepatocellular carcinoma is sorafenib monotherapy. The study was conducted to assess the efficacy and safety of the novel combination of sorafenib and gemcitabine in the treatment of advanced hepatocellular carcinoma. METHODS:Between March 2008 and Octo...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1111/ajco.12191

    authors: Srimuninnimit V,Sriuranpong V,Suwanvecho S

    更新日期:2014-09-01 00:00:00

  • Human papillomavirus promotes esophageal squamous cell carcinoma by regulating DNA methylation and expression of HLA-DQB1.

    abstract:AIMS:Esophageal cancer (EC) is one of the most prevalent and deadly cancers worldwide. Along with nutrition, smoking and alcohol consumption, human papillomavirus (HPV) infection is one of the major risk factors, which is modulated by host immune response. This study is aimed at elucidating how HPV modifies host immune...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/ajco.12135

    authors: Feng B,Awuti I,Deng Y,Li D,Niyazi M,Aniwar J,Sheyhidin I,Lu G,Li G,Zhang L

    更新日期:2014-03-01 00:00:00

  • Positive sentinel lymph node metastasis from a metastasis in Melanoma.

    abstract::The rationale for certain patterns of metastatic spread seen in melanoma is not well understood. Currently, there is no clear experimental evidence to support the potential for metastases to form metastases in this disease. We report a case of a 31-year-old woman, with metastatic melanoma, who developed axillary lymph...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/ajco.12169

    authors: Bowyer S,Feeney K,Millward M

    更新日期:2014-12-01 00:00:00

  • Comparing single-agent with doublet chemotherapy in first-line treatment of advanced non-small cell lung cancer with performance status 2: a meta-analysis.

    abstract:AIM:This systematic review and meta-analysis was performed to assess the efficacy and side effects between single-agent and doublet chemotherapy in first-line treatment of advanced non-small cell lung cancer with performance status 2 (PS2). METHODS:We searched for randomized controlled trials in online electronic data...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1111/ajco.12359

    authors: Luo L,Hu Q,Jiang JX,Yang X,Dinglin XX,Lin X,Yao HR

    更新日期:2015-09-01 00:00:00

  • Pilot study evaluating the role of cardiac magnetic resonance imaging in monitoring adjuvant trastuzumab therapy for breast cancer.

    abstract:AIM:To explore the incidence of subclinical cardiotoxicity in women treated with adjuvant trastuzumab in the early breast cancer setting using cardiac magnetic resonance imaging (cMRI). METHODS:The cardiac function and myocardial tissue characteristics of 25 women who had completed adjuvant trastuzumab therapy greater...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/j.1743-7563.2011.01462.x

    authors: Lawley C,Wainwright C,Segelov E,Lynch J,Beith J,McCrohon J

    更新日期:2012-03-01 00:00:00

  • Changes in DNA methylation after 6-week exercise training in colorectal cancer survivors: A preliminary study.

    abstract:AIM:Behavioral interventions such as exercise may induce epigenetic changes. Only few studies investigated the effects of exercise on epigenetic alterations in colorectal cancer survivors. The aim of this study was to explore the changes of genome-wide DNA methylation after 6-week exercise training in colorectal cancer...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/ajco.13482

    authors: Hwang SH,Kang DW,Lee MK,Byeon JY,Park H,Park DH,Kim KC,Lee ST,Chu SH,Kim NK,Jeon JY

    更新日期:2020-10-13 00:00:00

  • Infliximab for ipilimumab-induced colitis: A series of 13 patients.

    abstract:OBJECTIVE:To review the outcomes of metastatic melanoma patients treated with infliximab for severe steroid-refractory colitis secondary to ipilimumab therapy. BACKGROUND:Immune-related colitis is a known potential adverse effect of ipilimumab, that causes significant morbidity and extended hospital stays. There are l...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/ajco.12651

    authors: Hillock NT,Heard S,Kichenadasse G,Hill CL,Andrews J

    更新日期:2017-10-01 00:00:00

  • Prevalence of autoimmune hemolytic anemia in multiple myeloma: A prospective study.

    abstract:AIM:Autoimmune hemolytic anemia (AIHA) is frequently associated with B-cell lymphoproliferative disorders, and patients rarely develop overt clinical manifestations of AIHA. AIHA is rare in patients with multiple myeloma (MM). We conducted a prospective study to detect the presence of AIHA in MM patients and its impact...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/ajco.12230

    authors: Kashyap R,Singh A,Kumar P

    更新日期:2016-06-01 00:00:00

  • Salvage stereotactic body radiotherapy for locally recurrent uterine cervix cancer at the pelvic sidewall: Feasibility and complication.

    abstract:AIMS:To determine the feasibility of stereotactic body radiotherapy (SBRT) in patients with pelvic sidewall recurrence of uterine cervical cancer after radical hysterectomy or definitive radiotherapy. METHODS:We retrospectively reviewed 23 patients with locally recurrent uterine cervical cancer limited to the pelvic s...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/ajco.12185

    authors: Seo Y,Kim MS,Yoo HJ,Jang WI,Rhu SY,Choi SC,Kim MH,Kim BJ,Lee DH,Cho CK

    更新日期:2016-06-01 00:00:00

  • Differentiating malignant colorectal tumor patients from benign colorectal tumor patients by assaying morning urinary arylsulfatase activity.

    abstract:AIM:For several decades urinary arylsulfatase (ARS) activity has been reported to be elevated in many cancers. It has been shown that urinary ARS activity may serve as a marker of tumor progression and therapy surveillance. This study was designed to evaluate the clinical application of detection of urinary ARS activit...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/j.1743-7563.2012.01545.x

    authors: Niu R,Jing H,Chen Z,Xu J,Dai J,Yan Z

    更新日期:2012-12-01 00:00:00

  • Correlations between CD4+ FoxP3+ Treg and expression of FoxM1 and Ki-67 in gastric cancer patients.

    abstract:AIMS:In this study, we intended to analyze the clinical significance of CD4+ FoxP3+ Tregs in gastric cancer patients and investigate the relationship between the proportion of CD4+ FoxP3+ Tregs in the peripheral blood and the expression of FoxM1 and Ki-67 in gastric cancer tissues. METHODS:Flow cytometry was used to m...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/ajco.13302

    authors: Ma K,Li X,Lv J,Liu Z,Zhang L,Cong H,Wang H,Shen F,Yue L

    更新日期:2020-01-19 00:00:00

  • A study on the association between hyperlipidemia and hypothyroidism and the response to TKIs in metastatic renal cell carcinoma.

    abstract:AIM:Vascular endothelial growth facto receptor-tyrosine kinase inhibitors (VEGFR-TKIs) are widely used for metastatic renal cell carcinoma (mRCC). The aim of this study was to investigate the association between the response to VEGFR-TKIs and hyperlipidemia and hypothyroidism. METHODS:Clinical data on 155 patients wit...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/ajco.12473

    authors: Song Y,Du C,Zhang W,Sun Y,Yang L,Cui C,Chi Y,Shou J,Zhou A,Wang J,Sun Y

    更新日期:2016-06-01 00:00:00

  • Potential issues with complementary medicines commonly used in the cancer population: A retrospective review of a tertiary cancer center's experience.

    abstract:AIM:Complementary medicine (CAM) use in the cancer population is higher than the general population: some studies estimate up to 70%. Our Medicines Information Centre, in a tertiary cancer institution, receives many enquiries regarding use and safety of CAM with conventional cancer therapies (chemotherapy, radiotherapy...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/ajco.13026

    authors: Brooks SL,Rowan G,Michael M

    更新日期:2018-10-01 00:00:00

  • Effect of pre existing respiratory conditions on survival of lung cancer patients: A nationwide population-based cohort study.

    abstract:BACKGROUND:Common diseases with potential to increase the risk of death from lung cancer have so far not been studied in large populations. METHODS:We did a population-based retrospective cohort study using nationwide health insurance claims data from 2005 to 2012 in Korea including 205 403 lung cancer patients. Multi...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/ajco.12697

    authors: Hong S,Park EC,Kim TH,Kwon JA,Yoo KB,Han KT,Yoo JW,Kim SJ

    更新日期:2018-04-01 00:00:00

  • Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced non-small-cell lung cancer receiving first-line gefitinib or erlotinib treatment.

    abstract:AIM:Elevated neutrophil-to-lymphocyte ratio (NLR) has been demonstrated to be a poor prognostic factor in multiple types of malignancies, whereas the effect of NLR on the prognosis of epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) patients treated with first-line EGFR tyrosi...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/ajco.12273

    authors: Lin GN,Peng JW,Liu PP,Liu DY,Xiao JJ,Chen XQ

    更新日期:2017-10-01 00:00:00

  • Syndrome of inappropriate anti-diuretic hormone secretion secondary to carboplatin after docetaxel-carboplatin-trastuzumab combination for early stage HER-2 positive breast cancer.

    abstract::Carboplatin is a platinum analogue, widely used in the treatment of numerous cancer types including lung, genitourinary and ovarian cancers. It is also used in the adjuvant treatment of human epidermal growth factor receptor 2 positive breast cancer, where a non-anthracycline regimen is preferred. It is considered gen...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/j.1743-7563.2012.01526.x

    authors: Turner N,Stewart J,Barnett F,White S

    更新日期:2012-09-01 00:00:00

  • Oxaliplatin/5-fluorouracil-based adjuvant chemotherapy as a standard of care for colon cancer in clinical practice: Outcomes of the ACCElox registry.

    abstract:AIM:The ACCElox registry was set up to assess therapeutic management of early-stage colon cancer with oxaliplatin/5-fluorouracil (5-FU)-based regimen and the duration of adjuvant chemotherapy in current clinical practice. METHODS:This prospective observational study was conducted between 2006 and 2008 in 19 countries ...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1111/ajco.12409

    authors: Park YS,Ji J,Zalcberg JR,El-Serafi M,Buzaid A,Ghosn M

    更新日期:2015-12-01 00:00:00

  • A phase I and II trial of epirubicin, cisplatin, 24-hour infusion 5 fluorouracil and sodium folinate in patients with advanced esophagogastric carcinomas.

    abstract:AIM:Advanced esophagogastric carcinoma has a poor prognosis. Palliative chemotherapy provides a survival advantage and improved quality of life. Epirubicin, cisplatin and continuous infusional 5-fluorouracil (5-FU) (ECF) is a well-established chemotherapy regimen but a continuous chemotherapy infusion is not always fea...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/j.1743-7563.2010.01340.x

    authors: Karapetis CS,Cheong KA,Yip D,Strickland AH,Steer C,Marx G,Yip S,Chrystal K,Harper PG

    更新日期:2010-12-01 00:00:00

  • Acute inflammatory demyelinating polyradiculoneuropathy in a patient receiving oxaliplatin-based chemotherapy.

    abstract::We report a case of acute inflammatory demyelinating polyradiculoneuropathy (AIDP) that developed in a patient with cholangiocarcinoma after receiving oxaliplatin-based chemotherapy. A 62-year-old man had multiple hypodense lesions with delayed enhancement in the both lobes of the liver on abdominal computed tomograph...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/j.1743-7563.2011.01515.x

    authors: Yoon JY,Nam TS,Kim MK,Hwang JE,Shim HJ,Cho SH,Chung IJ,Bae WK

    更新日期:2012-06-01 00:00:00

  • Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer.

    abstract::First-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are used as first-line therapy in patients with non-small cell lung cancer (NSCLC) harboring a sensitizing mutation in the EGFR gene. Unfortunately, resistance to these therapies often occurs within 10 months of commencing treat...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章,评审

    doi:10.1111/ajco.12699

    authors: John T,Bowden JJ,Clarke S,Fox SB,Garrett K,Horwood K,Karapetis CS

    更新日期:2017-08-01 00:00:00

  • Upfront maintenance therapy with arsenic trioxide in acute promyelocytic leukemia provides no benefit for non-t(15;17) subtype.

    abstract:AIMS:The optimal maintenance therapy for patients with acute promyelocytic leukemia (APL) who achieved complete remission (CR) and complete consolidation chemotherapy is still controversial. Whether the use of arsenic trioxide (ATO) alone or along with all-trans retinoic acid (ATRA) improves overall survival (OS) or di...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/j.1743-7563.2011.01496.x

    authors: Chiang YH,Chang YF,Hsieh RK,Lin J,Chen CG,Lim KH,Lin HC,Chang MC

    更新日期:2012-12-01 00:00:00

  • Toxicity profile differences of adjuvant docetaxel/cyclophosphamide (TC) between Asian and Caucasian breast cancer patients.

    abstract:AIM:For early-stage breast cancer, four cycles of docetaxel and cyclophosphamide (TC) was proven superior to doxorubicin plus cyclophosphamide in the US Oncology 9375 trial. Given primary prophylactic antibiotics, 5% febrile neutropenia was recorded in a population comprising 75.5% Caucasians. Smaller trials and retros...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/ajco.12682

    authors: Chow LWC,Biganzoli L,Leo AD,Kuroi K,Han HS,Patel J,Huang CS,Lu YS,Zhu L,Chow CYC,Loo WTY,Glück S,Toi M

    更新日期:2017-12-01 00:00:00

  • An exploration of the dynamics and influences upon second medical opinion consultations in cancer care.

    abstract:AIM:The aim of this study was to explore the dynamics within second medical opinion consultations in patients with cancer. METHODS:Semi-structured interviews were held with four oncologists and were subjected to a thematic analysis to define the broad issues. These formed the basis of a survey distributed to Australia...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/j.1743-7563.2010.01330.x

    authors: Philip J,Gold M,Schwarz M,Komesaroff P

    更新日期:2011-03-01 00:00:00

  • Serious hepatic complications of selective internal radiation therapy with yttrium-90 microsphere radioembolization for unresectable liver tumors.

    abstract:AIM:Selective internal radiation therapy with yttrium-90 microsphere radioembolization has been used to treat unresectable liver tumors and its acute toxicity has been well described. Subacute and long-term hepatic complications related to radioembolization however may be underreported in the literature. This retrospec...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/ajco.12229

    authors: Kuo JC,Tazbirkova A,Allen R,Kosmider S,Gibbs P,Yip D

    更新日期:2014-09-01 00:00:00

  • Oral cyclophosphamide in recurrent ovarian cancer.

    abstract:AIMS:Cyclophosphamide was widely used as a single agent prior to the advent of platinum-based regimens for epithelial ovarian cancer, and, in combination with platinum, prior to the adoption of platinum and paclitaxel as standard first-line therapy. As cyclophosphamide currently has no defined role in ovarian cancer we...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1111/ajco.12074

    authors: Handolias D,Quinn M,Foo S,Mileshkin L,Grant P,Dutu G,Rischin D

    更新日期:2016-03-01 00:00:00

  • Posterior reversible encephalopathy syndrome following chemotherapy with oxaliplatin and a fluoropyrimidine: a case report and literature review.

    abstract::Posterior reversible encephalopathy syndrome (PRES) is a neuro-radiological syndrome characterized by seizures, altered level of consciousness and visual disturbance. PRES is associated with hyperintense lesions on magnetic resonance imaging (MRI) most commonly seen in the posterior regions. In most cases symptoms and...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章,评审

    doi:10.1111/j.1743-7563.2012.01544.x

    authors: Femia G,Hardy TA,Spies JM,Horvath LG

    更新日期:2012-06-01 00:00:00

  • Radiation oncology during COVID-19: Strategies to avoid compromised care.

    abstract::The COVID-19 pandemic will present a range of challenges to radiation oncology departments. Early data suggest that cancer patients carry a higher than average, but still low absolute risk of hospitalization from COVID-19. The risk of severe events for those who are hospitalized however, is high. Resources for usual c...

    journal_title:Asia-Pacific journal of clinical oncology

    pub_type: 杂志文章,评审

    doi:10.1111/ajco.13456

    authors: Horsley PJ,Back M,Lamoury G,Porter B,Booth J,Eade TN

    更新日期:2021-02-01 00:00:00